好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Evolution of a Multiple Sclerosis Relapse: Analysis of Clinical & Patient-reported Outcome Measures
Multiple Sclerosis
P2 - Poster Session 2 (11:45 AM-12:45 PM)
6-005
To investigate changes in functional and patient-reported outcome measures (PROMs) following a multiple sclerosis (MS) relapse. 
Improved understanding of the recovery process after a relapse may guide interventions to promote recovery and limit the sequalae of an incomplete recovery

This retrospective study identified MS patients with a provider-reported relapse from May 2016 - June 2022. Baseline characteristics were defined 12 months prior to the relapse and compared at 12-month post-relapse. Controls were MS patients without a relapse and had follow-up data available over 24 months. Changes in Quality of Life in Neurological Disorders Questionnaire (Neuro-QoL) and MS Performance Test (MSPT) measures were compared between the relapsing and non-relapsing cohort using multivariable linear regression models adjusted for age, sex, race, disease modifying use, MS phenotype, and Patient Determined Disease Steps (PDDS). Acute treatment information was not available.

1617 MS patients were included: 180 (11.1%) in the relapsing cohort (age 42.2 ± 10.8, 78.3% female, 80.6% white, baseline PDDS 1.0 [0.0, 3.0]) compared to 1,437 (88.9%) in the non-relapsing cohort (age 49.8 ± 12.5, 71.6% female, 83.9% white, baseline PDDS 2.0 [0.0, 4.0]). A total of 56 (32.2%) in the relapsing cohort had at least a 1-point increase in PDDS compared to 341 (24.2%) in the non-relapsing cohort (p = 0.02) at follow-up. After adjustment, the relapsing cohort had a clinically significant decline in Neuro-QoL (≥ 5 T-score change) on all functional and symptomatic domains except positive affect compared to the non-relapsing cohort. There was no difference between the two groups in MSPT including manual dexterity, processing speed, and walking speed tests (p > 0.05).   
MS patients with a recent relapse demonstrate similar performance outcomes but poorer PROMs compared to those without relapse. These findings highlight the range of symptoms that are impacted following a relapse.
Authors/Disclosures
Justin Abbatemarco, MD
PRESENTER 		Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech . Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics, Inc.. Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. The institution of Dr. Abbatemarco has received research support from Amgen.
Carol Swetlik, MD (Cleveland Clinic) An immediate family member of Dr. Swetlik has received personal compensation for serving as an employee of Pfizer. Dr. Swetlik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech. Dr. Swetlik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen.
Daniel Ontaneda, MD, PhD, FAAN (Cleveland Clinic) Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Ontaneda has received research support from NIH. The institution of Dr. Ontaneda has received research support from PCORI. The institution of Dr. Ontaneda has received research support from NMSS. The institution of Dr. Ontaneda has received research support from Genetech.
Robert A. Bermel, MD, FAAN (Cleveland Clinic) Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Bermel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Bermel has received research support from Biogen. The institution of Dr. Bermel has received research support from Roche. The institution of Dr. Bermel has received research support from Novartis. Dr. Bermel has received intellectual property interests from a discovery or technology relating to health care.
Sarah M. Planchon Pope, PhD, CCRP (Cleveland Clinic) Dr. Planchon Pope has nothing to disclose.
Scott Husak Scott Husak has nothing to disclose.
Brittany Lapin No disclosure on file
Yadi Li No disclosure on file
Deborah M. Miller, PhD (Cleveland Clinic Foundation) Dr. Miller has received intellectual property interests from a discovery or technology relating to health care.